- CEO
- Mike Khanna
- Full Time Employees
- 21
- Sector
- Technology
- Industry
- Information Technology Services
- Address
- 1735 North First Street San Jose CA United States of America 95112
- IPO Date
- Sep 4, 2014
- Business
- Sonasoft Corporation (SSFT) develops artificial intelligence software platforms and provides related professional services to enterprise customers in the United States and internationally. The company offers its flagship NuGene AI platform, a real-time AI solution for data ingestion from structured and unstructured sources, data transformation, search, reporting, analysis, alerting, and supervised machine learning to deliver business insights across security, compliance, insurance, infrastructure, software development, IT operations, applications management, and business analytics; its SAIBRE AI ecosystem, an AI build and runtime platform supporting bot deployment for enterprise applications including healthcare inventory management and dynamic pricing; data archiving software; managed services encompassing hardware, software, and IT advisory; and professional services such as data engineering, migrations for email, user archives, PST data, SQL workloads, and domains to cloud platforms including Microsoft, Google, and Amazon. Sonasoft targets small and medium enterprises, ERP providers, original equipment manufacturers, IT professionals, security teams, application developers, manufacturing firms, and business users seeking real-time operational intelligence, risk mitigation, process automation, and revenue optimization. Founded in 2002 and headquartered in San Jose, California, the company operates from additional locations in the Philippines, India, and Pakistan. In recent developments, Sonasoft sold its wholly-owned subsidiary Cornerstone Technologies in October 2022 for $730,000 cash to streamline operations and focus exclusively on AI solutions; voluntarily delisted from the OTCQB market in March 2023 to trade on the OTC Pink market, citing cost savings, reduced regulatory burdens, and enhanced private growth opportunities; raised $1.5 million from restricted common stock sales and $1 million from preferred stock to eliminate over $10 million in liabilities; and entered a letter of intent in 2022 for a strategic AI partnership with Diagnose Early to apply SAIBRE for early disease detection using health data from Nobel Prize-winning research teams.